NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Therapeutic Targets in African-American Youth with Type 2 Diabetes

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

17-DK-0013

Sponsoring Institute

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 12
Max Age: 25

Referral Letter Required

No

Population Exclusion(s)

White;
Native Hawaiian/Pacific Islander;
Hispanic or Latino;
Asian;
American Indian or Alaskan Native

Special Instructions

Currently Not Provided

Keywords

Diabetes;
Metformin;
Glucose

Recruitment Keyword(s)

None

Condition(s)

Type 2 Diabetes

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Drug: Metformin and Liraglutide
Drug: Metformin

Supporting Site

National Institute of Diabetes and Digestive and Kidney DiseasesChildren's National Medical Center (CNMC)

Background:

The pill metformin treats diabetes. But it does not work for all youth, especially African-Americans. The injectable Liraglutide treats type 2 diabetes in adults. Researchers want to understand how these drugs work and if they decrease excess sugar made by the liver in youth with type 2 diabetes.

Objective:

To test if using liraglutide and metformin are better than just metformin for decreasing excess sugar produced by the liver in African-American youth with type 2 diabetes.

Eligibility:

African-Americans ages 12-21 with type 2 diabetes

Design:

Visit 1: Participants will be screened with medical history, physical exam, and blood and urine tests.

Participants will stop taking diabetes medicines for 1 week. They will learn how to check blood sugars at home twice a day.

Visit 2: Overnight at the clinic. Participants will have:

Vital signs taken.

Pregnancy test.

A thin plastic tube (IV catheter) be inserted in each forearm by needle.

Blood drawn several times after drinking a sweet drink.

X-ray of total body fat.

Urine and stool collected.

Breath tests while wearing a clear hood for up to 45 minutes.

For several hours, participants can have only water. At 4 a.m. they will get sugar and fat with nonradioactive isotopes in one IV. Blood will be collected. Every 30 minutes from 9 a.m. to 2 p.m., they will drink small amounts of a shake and have blood drawn.

Participants will be randomly assigned to take either both study drugs daily or just metformin daily.

Visits 3-4: Participants will bring their blood sugar records and have blood tests.

Visit 5, after 3 months: Repeat of visit 2.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

1. Youth must self-identify as African-American and identify both parents as African-American

2. Age 12-25 years

3. Pubertal or post-pubertal: Girls Tanner stage IV-V breast; Boys Testicular volume 11-25cc

4. Diagnosis of type 2 diabetes of less than or equal to 5 years duration, as per American Diabetes Association Criteria

5. Hemoglobin A1C <9% at study initiation

6. Negative to mild ketonuria without acidosis (negative or 1+ ketones on urinalysis)

7. Negative test for diabetes-related autoantibodies (glutamic acid decarboxylase 65 and tyrosine phosphataserelated islet antigen 2 (IA-2))

8. Willing and able to take daily medications and check blood glucose levels at least twice per day or wear a continuous glucose monitoring device (CGM).

EXCLUSION CRITERIA:

1. Pregnancy or breastfeeding

2. Allergy to study medications

3. Allergy to milk protein

4. Chronic insulin therapy

5. Treatment with other medications which are known to affect the parameters under study (for example sodiumglucose transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-IV) inhibitors, non-selective beta blockers).

6. Metabolic derangement such as metabolic acidosis, severe hyperglycemia (fasting blood glucose greater than or equal to 200mg/dL), and/or liver enzymes > three times the upper limit of normal.

7. Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2

8. Any other condition that, in the opinion of the investigators, will increase risk to the subject, or impede the accurate collection of study-related data.

9. Body weight greater than or equal to 450 lbs

10. Body weight less than or equal to 58kg

11. Serum triglyceride concentrations greater than or equal to 500mg/dl

12. Hemoglobin concentration <11g/dL


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Stephanie T. Chung, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)



Stephanie T. Chung, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
BG 10-CRC RM 5-5940
10 CENTER DR
BETHESDA MD 20814
(240) 479-8137
stephanie.chung@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010
PRPL@cc.nih.gov

Clinical Trials Number:

NCT02960659

--Back to Top--